Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitors
- 4 April 2024
- journal article
- review article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 147, 107332
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Small-molecule agents for cancer immunotherapyActa Pharmaceutica Sinica B, 2023
- Local Release of TGF‐β Inhibitor Modulates Tumor‐Associated Neutrophils and Enhances Pancreatic Cancer Response to Combined Irreversible Electroporation and ImmunotherapyAdvanced Science, 2022
- Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 studyInvestigational New Drugs, 2019
- Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI)Bioorganic & Medicinal Chemistry, 2018
- Activin A regulates microRNAs and gene expression in LNCaP cellsThe Prostate, 2016
- TGF-β1 induces erlotinib resistance in non-small cell lung cancer by down-regulating PTENBiomedicine & Pharmacotherapy, 2016
- 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinaseBioorganic & Medicinal Chemistry, 2014
- 5-(1,3-Benzothiazol-6-yl)-4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole derivatives as potent and selective transforming growth factor-β type I receptor inhibitorsBioorganic & Medicinal Chemistry, 2012
- Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitorsBioorganic & Medicinal Chemistry, 2010
- Design, synthesis, and biological evaluation of novel 2-pyridinyl-[1,2,4]triazoles as inhibitors of transforming growth factor β1 type 1 receptorBioorganic & Medicinal Chemistry, 2004